We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Origin and progression
- What is the origin of primary disease?
- Ovarian cancer (1)
- The origin of most of the ovarian cancer cell? (1)
- Origin (1)
- Origin (2)
- How are the tumors reaching the ovary?
- Potential sources of progenitor cells
- p53 signature
- High grade serous ovarian cancer
- Why to the ovaries?
- What is the origin of ovarian cancer?
- Cancer stem cells in the fallopian tubes
- Cancer stem cells migrate to the ovaries (1)
- Epithelial mesenchymal transition
- In vitro differentiation into mesenchymal cells
- Epithelial ovarian cancer cells (1)
- Epithelial ovarian cancer cells (2)
- Epithelial ovarian cancer cells (3)
- CD44 positive cells are mesenchymal cells
- CD44+ vs CD44- (1)
- The cancer cells create spheroid structures
- Migration test
- Molecular characterization of EMT differentiation
- Expression of mesenchymal markers (1)
- Expression of mesenchymal markers (2)
- TWIST-1
- Cancer stem cells migrate to the ovaries (2)
- What allows the formation of ovarian tumors? (1)
- Epidemiological data
- Intra-uterin injection of CD44+ cells
- 24 hours
- 48 hours
- 5 days post-ovulation (1)
- 5 days post-ovulation (2)
- Tumor formation (1)
- Tumor formation (2)
- Tumor formation (3)
- Summary
- Ovarian tumors
- What allows the formation of ovarian tumors? (2)
- Early events in tumor cell attachment
- Effect of ovulation on tumor formation
- Cancer stem cells seed in the corpus luteum (1)
- Cancer stem cells seed in the corpus luteum (2)
- Cancer stem cells seed in the corpus luteum (3)
- Luteal cells (1)
- Luteal cells (2)
- Surface of the ovary is sealed (1)
- Surface of the ovary is sealed (2)
- The tumor is inside the ovary (1)
- The tumor is inside the ovary (2)
- The tumor is inside the ovary (3)
- The tumor is inside the ovary (4)
- The tumor is inside the ovary (5)
- The tumor is inside the ovary (6)
- Cancer stem cells migrate to the ovaries (3)
- Process of metastasis in ovarian cancer (1)
- Carcinomatosis
- Intra-peritoneal injection of CD44+ cells (1)
- Intra-peritoneal injection of CD44+ cells (2)
- Intra-peritoneal injection of CD44+ cells (3)
- Metastatic process (1)
- Metastatic process (2)
- Cancer cells attached to adipocytes (1)
- Cancer cells attached to adipocytes (2)
- Seeding of cancer stem cells in the abdomen
- Cancer stem cells migrate to the ovaries (4)
- Stages for ovarian cancer formation
- Response to chemotherapy (1)
- Response to chemotherapy (2)
- Co-culture model
- Co-culture 24h
- Co-culture 48h
- Co-culture 72h
- Co-culture 96h
- Co-culture 48h Taxol treatment
- Co-culture 72h Taxol treatment
- Co-culture 96h Taxol treatment
- In vivo treatment
- Cancer stem cells (1)
- Question
- Chemo-resistant cells & mesenchymal phenotype
- Primary tumors vs recurrence (1)
- Primary tumors vs recurrence (2)
- Expression of vimentin
- Vimentin expression in human recurrence
- Cancer stem cells (2)
- Cancer stem cells: recurrence
- Conclusion
- Targeting cancer stem cells to prevent recurrence
Topics Covered
- The origin of ovarian cancer
- Epithelial ovarian cancer cells
- The formation of ovarian tumors
- Luteal cells and ovarian cancer
- The metastatic process in ovarian cancer
- Response to chemotherapy
- The recurrence of cancer stem cells
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Mor, G. (2019, July 31). Ovarian cancer: progression of tumors [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved December 10, 2024, from https://doi.org/10.69645/SXPK9138.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Gil Mor has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Ovarian cancer: progression of tumors
Published on July 31, 2019
35 min
Other Talks in the Series: The Female Reproductive System: from Basic Science to Fertility Treatments
Transcript
Please wait while the transcript is being prepared...
0:05
Let me discuss quickly about
this question of the origin and progression of ovarian cancer.
0:13
Where is ovarian cancer originated?
Where are these stem cells coming from that will form
these ovarian tumors and then give origin to this disseminated disease,
that are the characteristics of ovarian cancer?
0:31
Ovarian cancer is defined as a single disease and
all the therapeutic approaches are the same for all the ovarian cancer patients.
Moreover, the discovery of markers for the disease has been
focused on a single type of markers
that will recognize all the different types of disease.
What do I mean with different types of disease?
When we look at the histology of ovarian cancer, they are different.
There is ovarian cancer mucinous,
there is ovarian cancer endometrioid,
there is ovarian cancer clear cell carcinomas,
and there is ovarian cancer high-grade serous.
But again, all of them we call them ovarian cancer and we treat them exactly the same.
1:20
The traditional view for the origin of the ovarian cancer has been that,
the surface epithelium of the ovaries,
during the repair at the time of ovulation will create invaginations within the tumor.
These invaginations will become malignant and from these epithelial invaginations,
you will have a serous ovarian cancer,
an endometrioid ovarian cancer,
a clear cell carcinoma, a transitional,
and even a mucinous,
from the same epithelium.
We go further a few years and around 2009,